Efficacy and tolerability of everolimus [Xience V] vs sirolimus [Cypher] drug eluting stents for the prevention of coronary artery restenosis and cardiovascular events in patients undergoing percutaneous coronary interventions: APPENDIX-AMI
Phase of Trial: Phase III
Latest Information Update: 13 Dec 2011
At a glance
- Drugs Everolimus (Primary) ; Sirolimus (Primary)
- Indications Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms APPENDIX-AMI
- 13 Dec 2011 New source identified and integrated (Netherlands Trial Register).
- 13 Dec 2011 Planned end date (Jun 2012) added as reported by Netherlands Trial Register record.
- 13 Dec 2011 Planned number of patients 2000, lead trial centre, actual initiation date 1 Dec 2007 added as reported by Netherlands Trial Register record.